Royalty Pharma plc (NASDAQ:RPRX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Royalty Pharma plc (NASDAQ:RPRX) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $41.67.

A number of research firms have weighed in on RPRX. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. Citigroup dropped their target price on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, October 25th.

Royalty Pharma Stock Up 2.6 %

Shares of NASDAQ RPRX opened at $24.92 on Wednesday. The firm has a fifty day simple moving average of $26.43 and a two-hundred day simple moving average of $27.15. Royalty Pharma has a 12 month low of $24.05 and a 12 month high of $31.66. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $14.68 billion, a PE ratio of 12.91, a price-to-earnings-growth ratio of 4.36 and a beta of 0.46.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Friday, November 15th were given a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 3.37%. The ex-dividend date was Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RPRX. Charles Schwab Investment Management Inc. grew its holdings in shares of Royalty Pharma by 58.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock valued at $84,915,000 after buying an additional 1,103,341 shares during the last quarter. Two Sigma Advisers LP boosted its stake in Royalty Pharma by 44.7% during the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock valued at $85,809,000 after purchasing an additional 936,900 shares during the last quarter. New South Capital Management Inc. increased its holdings in shares of Royalty Pharma by 60.7% in the 2nd quarter. New South Capital Management Inc. now owns 2,348,977 shares of the biopharmaceutical company’s stock worth $61,943,000 after purchasing an additional 887,522 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Royalty Pharma in the third quarter worth $14,898,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Royalty Pharma by 6.1% during the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock valued at $205,562,000 after purchasing an additional 417,490 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.